Modified Vaccinia Ankara (MVA) Vaccine Study
This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).
Nasopharyngeal Neoplasms|Epstein-Barr Virus Infections
DRUG: MVA Vaccine
To determine safety and to characterise the toxicity profile of MVA-EBNA1/LMP2 vaccine, 4 years
To describe changes in the frequency of functional T-cell responses to MHC class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during and up to nine months after the vaccination course., 4 years|To assess changes in levels of EBV genome levels in plasma, 4 Years
This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).